Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
Interventions: DRUG: Fluzoparib|DRUG: Fluzoparib+Camrelizumab
Sponsor: wang shusen